Akebia Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
245 1st St Ste 1400, Cambridge, Massachu...Phone Number
(617) 871-2098Website
www.akebia.comRevenue
$219.1 MillionStock Symbol
AKBAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, commercializing, and delivering innovative therapies for people living with kidney disease. The company focuses on addressing significant unmet medical needs associated with chronic kidney disease through scientific research, pharmaceutical development, commercialization expertise, and strategic collaborations. By combining research capabilities with commercial operations, Akebia has established an integrated business model that enables it to advance therapies from clinical development through regulatory approval and market commercialization while maintaining a strong commitment to improving patient outcomes.Explore more
Akebia Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Akebia Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Akebia Therapeutics recently announced quarterly report
Check out if Akebia Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Akebia Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Akebia Therapeutics
Akebia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Akebia Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Akebia Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Akebia Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Akebia Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Akebia Therapeutics
Compare insights from companies similar to Akebia Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Akebia Therapeutics
$219.1M
51-200
Public
$155M
2007
EO
Erik OstrowskiSenior Vice President, Chief Financial Officer and Chief Business Officer
Company Profile Activity
Activity Insights
Akebia Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Akebia Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Akebia Therapeutics.
Akebia Therapeutics financials insights
Gather financial insights about Akebia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$100M
2024
Debt
$55M
Akebia Therapeutics Tech Stack
A closer look at the technologies used by Akebia Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Person-Based
Carolyn Rucci Senior Vice President, Chief Legal Officer and Secretary, listed as agent for service.
Legal Affairs, Legal Counsel
Project
Laboratory Operations, Medical Research, Clinical Operations
Akebia Therapeutics News & Media
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026.Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapyAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2 newly-hired employees options to purchase an aggregate of 61,000 shares of Akebia’s common stock on July 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Akebia Therapeutics
Sign Up For FreeTo access detailed company insights
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, commercializing, and delivering innovative therapies for people living with kidney disease. The company focuses on addressing significant unmet medical needs associated with chronic kidney disease through scientific research, pharmaceutical development, c... Read More
